Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036114 · ClinicalTrials.gov registry record · Phase 3
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00036114 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization.
The verdict
NCT00036114, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
Interventions
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-03 |
| Est. Completion | 2003-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036114
The ClinicalTrials.gov registry entry for NCT00036114 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aripiprazole is the first listed.
NCT00036114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036114 about?
NCT00036114 is a clinical study titled "Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type". The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
What is the current status of trial NCT00036114?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-03. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00036114?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00036114?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.